RPL22L1 and neoplasm: The PDX samples were assembled into 5-FU sensitive (Tumor inhibition >64%) and 5-FU resistant (Tumor inhibition <30%) groups, which revealed that RPL22L1 expression was significantly higher in the 5-FU resistant group (p<0.05; Fig 4B and 4C; S1 and S2 Tables).